Article
Clinical Neurology
Marcus W. Koch, Pavle Repovic, Jop Mostert, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Summary: This study investigates the short-term variation in T25FW and NHPT using patient-level original trial data and compares it with disability change at 12-month follow-up in people with PPMS. The traditional =20% change threshold for T25FW and NHPT represents a reasonable compromise between reducing false change events and achieving a large number of change events during follow-up.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Anissa Kalinowski, Gary Cutter, Nina Bozinov, Jessica A. Hinman, Michael Hittle, Robert Motl, Michelle Odden, Lorene M. Nelson
Summary: The study confirms the association of the T25FW with disability and provides evidence of its predictive validity. Walk times in T25FW increased with age, disability, disease type, and disease duration.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Letter
Clinical Neurology
Cintia Ramari, Peter Feys, Tobias Gaemelke, Lars G. Hvid, Ilse Baert, Alon Kalron, Ulrik Dalgas
Summary: The T25WT can accurately predict long walking capacity in people with multiple sclerosis, with acceptable error rates. However, the accuracy decreases at higher levels of walking dysfunction, suggesting limitations in predicting walking ability in individuals with more severe impairments.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Marcus W. Koch, Jop P. Mostert, Jerry S. Wolinsky, Fred D. Lublin, Bernard Uitdehaag, Gary R. Cutter
Summary: This study compared the performance of EDSS with T25FW and NHPT in a large RRMS trial, finding that T25FW may be more effective, and that the Kaplan-Meier survival analysis method may exaggerate estimates of disability worsening.
Article
Clinical Neurology
Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Summary: This study found that using timed 25-foot walk (T25FW) as the primary outcome measure might be more useful than the Expanded Disability Status Scale (EDSS) in clinical trials for primary progressive MS (PPMS), and using T25FW could shorten the duration of clinical trials. Additionally, the presence of contrast-enhancing lesions (CELs) at baseline was associated with disability outcomes.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Robert G. Kaniecki, Deborah I. Friedman, Divya Asher, Joe Hirman, Roger Cady
Summary: This study investigates the clinical impact of reduced headache frequency to ≤ 4 monthly headache days as a treatment-related migraine prevention target goal. The results show that patients who achieved ≤ 4 monthly headache days reported less acute medication use and improved patient-reported outcomes, suggesting that ≤ 4 monthly headache days may be a useful treatment target for chronic migraine.
Article
Dermatology
Kenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, Makoto Kawashima
Summary: The background data from the Japanese phase 3 study showed that nemolizumab in combination with topical treatments can reduce pruritus in atopic dermatitis. This post-hoc analysis found that improvements in pruritus were associated with improvements in eczema symptoms, sleep quality, and daily life.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Review
Clinical Neurology
Marc Bolliger, Andrew R. Blight, Edelle C. Field-Fote, Kristin Musselman, Serge Rossignol, Dorothy Barthelemy, Laurent Bouyer, Milos R. Popovic, Jan M. Schwab, Michael L. Boninger, Keith E. Tansey, Giorgio Scivoletto, Naomi Kleitman, Linda A. T. Jones, Dany H. Gagnon, Sylvie Nadeau, Dirk Haupt, Lea Awai, Chris S. Easthope, Bjorn Zorner, Ruediger Rupp, Dan Lammertse, Armin Curt, John Steeves
Article
Medicine, General & Internal
R. J. Fox, C. S. Coffey, R. Conwit, M. E. Cudkowicz, T. Gleason, A. Goodman, E. C. Klawiter, K. Matsuda, M. McGovern, R. T. Naismith, A. Ashokkumar, J. Barnes, D. Ecklund, E. Klingner, M. Koepp, J. D. Long, S. Natarajan, B. Thornell, J. Yankey, R. A. Bermel, J. P. Debbins, X. Huang, P. Jagodnik, M. J. Lowe, K. Nakamura, S. Narayanan, K. E. Sakaie, B. Thoomukuntla, X. Zhou, S. Krieger, E. Alvarez, M. Apperson, K. Bashir, B. A. Cohen, P. K. Coyle, S. Delgado, L. D. Dewitt, A. Flores, B. S. Giesser, M. D. Goldman, B. Jubelt, N. Lava, S. G. Lynch, H. Moses, D. Ontaneda, J. S. Perumal, M. Racke, P. Repovic, C. S. Riley, C. Severson, S. Shinnar, V. Suski, B. Weinstock-Guttman, V. Yadav, A. Zabeti
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Clinical Neurology
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew D. Goodman, Rachel Farrell, Raymond Hupperts, Andrew R. Blight, Veronica Englishby, Manjit McNeill, Ih Chang, Gabriel Lima, Jacob Elkins
Article
Clinical Neurology
Caila B. Vaughn, Katelyn S. Kavak, Michael G. Dwyer, Aisha Bushra, Muhammad Nadeem, Diane L. Cookfair, Murali Ramanathan, Ralph H. B. Benedict, Robert Zivadinov, Andrew Goodman, Lauren Krupp, Robert W. Motl, Bianca Weinstock-Guttman, Bianca Weinstock-Guttman, Robert Zivadinov, Channa Kolb, Andrew Goodman, Jessica F. Robb, Burk Jubelt, Allen Gerber, Ilya Kister, Lauren Krupp, Lana Zhovtis Ryerson, Patricia Coyle, Allan Perel, Malcolm Gottesman, Michael Lenihan, Keith Edwards, Lore Garten, Mary Ann Picone, Holy Name
MULTIPLE SCLEROSIS JOURNAL
(2020)
Review
Clinical Neurology
Andrew R. Blight, Jane Hsieh, Armin Curt, James W. Fawcett, James D. Guest, Naomi Kleitman, Shekar N. Kurpad, Brian K. Kwon, Daniel P. Lammertse, Norbert Weidner, John D. Steeves
Article
Clinical Neurology
Jessica F. Robb, Megan H. Hyland, Andrew D. Goodman
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2019)
Article
Neurosciences
Ephron S. Rosenzweig, Ernesto A. Salegio, Justine J. Liang, Janet L. Weber, Chase A. Weinholtz, John H. Brock, Rod Moseanko, Stephanie Hawbecker, Roger Pender, Christina L. Cruzen, Jennifer F. Iaci, Anthony O. Caggiano, Andrew R. Blight, Barbara Haenzi, J. Russell Huie, Leif A. Havton, Yvette S. Nout-Lomas, James W. Fawcett, Adam R. Ferguson, Michael S. Beattie, Jacqueline C. Bresnahan, Mark H. Tuszynski
NATURE NEUROSCIENCE
(2019)
Article
Clinical Neurology
Christopher M. Perrone, Robert P. Lisak, Ethan Meltzer, Peter Sguigna, Etsegenet Tizazu, Dina Jacobs, Esther Melamed, Ashlea Lucas, Leorah Freeman, Gabriel Pardo, Andrew Goodman, Edward J. Fox, Kathleen Costello, Matthew S. Parsons, Scott S. Zamvil, Elliot M. Frohman, Teresa C. Frohman
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2019)
Article
Pharmacology & Pharmacy
Andrew D. Goodman, Nidhiben Anadani, Lee Gerwitz
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2019)
Article
Immunology
David Baker, Liaqat Ali, Gauri Saxena, Gareth Pryce, Meleri Jones, Klaus Schmierer, Gavin Giovannoni, Sharmilee Gnanapavan, Kathleen C. Munger, Lawrence Samkoff, Andrew Goodman, Angray S. Kang
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Clinical Neurology
Robert A. Bermel, Janel K. Fedler, Peter Kaiser, Cindy Novalis, Jeff Schneebaum, Elizabeth A. Klingner, Dawn Williams, Jon W. Yankey, Dixie J. Ecklund, Marianne Chase, Robert T. Naismith, Eric C. Klawiter, Andrew D. Goodman, Christopher S. Coffey, Robert J. Fox
Summary: The SPRINT-MS trial showed that ibudilast may attenuate retinal thinning in progressive multiple sclerosis, with changes in OCT outcomes favoring the ibudilast group over placebo. These findings suggest that OCT could be a viable outcome measure in progressive MS trials with therapies that have a significant treatment effect.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Review
Clinical Neurology
M. J. Mulcahey, Linda A. T. Jones, Frank Rockhold, Ruediger Rupp, John L. K. Kramer, Steven Kirshblum, Andrew Blight, Daniel Lammertse, James D. Guest, John D. Steeves
Article
Rehabilitation
Vieri Failli, Naomi Kleitman, Daniel P. Lammertse, Jane T. C. Hsieh, John D. Steeves, James W. Fawcett, Mark H. Tuszynski, Armin Curt, Michael G. Fehlings, James D. Guest, Andrew R. Blight
TOPICS IN SPINAL CORD INJURY REHABILITATION
(2021)
Article
Clinical Neurology
R. Zivadinov, N. Bergsland, J. R. Korn, M. G. Dwyer, N. Khan, J. Medin, J. C. Price, B. Weinstock-Guttman, D. Silva
AMERICAN JOURNAL OF NEURORADIOLOGY
(2018)